Top View
- Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
- (Trastuzumab-DM1) for Treatment of HER-2 Positive Malignancies
- MEK Inhibitors for the Treatment of Non-Small Cell Lung Cancer
- In Vivo Assessment of Potential for UGT-Inhibition-Based Drug-Drug Interaction Between Sorafenib and Tapentadol
- Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites Ana Carolina C
- Small Molecule Tyrosine Kinase Inhibitors of Erbb2/HER2/Neu in the Treatment of Aggressive Breast Cancer
- Preparation of Antibodies and Development of an Enzyme-Linked
- Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
- Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits
- A Study of Neratinib Plus Capecitabine Versus
- Tyrosine Kinase Inhibitor Family of Drugs As Prospective Targeted Therapy for COVID-19 Based on in Silico and 3D-Human Vascular Lung Model Studies
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
- VOTRIENT (Pazopanib) Tablets Gastrointestinal Perforation Or Fistula
- Tyverb, INN-Lapatinib
- Genetic Modifiers of EGFR Dependence in Non-Small Cell Lung Cancer
- In Gastric Cancer Positive for MET Amplification
- Synergistic Proapoptotic Effects of the Two Tyrosine Kinase Inhibitors Pazopanib and Lapatinib on Multiple Carcinoma Cell Lines
- A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients With
- Reimbursement Criteria for Frequently Requested Drugs
- Ado-Trastuzumab Emtansine (KADCYLA) Drug Monograph
- A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
- Cardio-Oncology Jo E
- Effectivity of Pazopanib Treatment in Orthotopic Models of Human
- Drug Information Center Highlights of FDA Activities – 4/1/2020
- Lapatinib (Tykerb®) EOCCO POLICY
- Enhertu, INN-Trastuzumab Deruxtecan
- Early Decline in Serum Phospho-CSE1L Levels in Vemurafenib/Sunitinib-Treated Melanoma and Sorafenib/Lapatinib-Treated Colorectal
- Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
- Fam-Trastuzumab Deruxtecan-Nxki (Enhertu®)
- Testican-1-Mediated Epithelial&Ndash;Mesenchymal Transition
- VOTRIENT in Patients VOTRIENT Safely and Effectively
- Therapeutic Drug Monitoring and Tyrosine Kinase Inhibitors (Review)
- The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
- Defining the Relationship Between the Bioactivation of Lapatinib by CYP3A
- KADCYLA (Ado-Trastuzumab Emtansine) and Not Trastuzumab
- Receptor Tyrosine Kinases (Rtks) in Breast Cancer
- NIH Public Access Author Manuscript Nature
- Oral Targeted Therapy for Cancer
- Tykerb® (Lapatinib Ditosylate Tablets)
- Delineation of Molecular Mechanisms of Sensitivity to Lapatinib in Breast Cancer Cell Lines Using Global Gene Expression Profiles
- Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured in Vitro
- Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis Benjamin Ruprecht1,2, Esther A
- Treatment and Side Effects
- Emtansine (T-DM1) Resistance in HER2-Positive Cancer
- Fam-Trastuzumab Deruxtecan-Nxki
- EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer
- Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib
- Imatinib Radiosensitizes Bladder Cancer by Targeting Homologous Recombination
- Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis
- Inhibition of C-ABL Sensitizes Breast Cancer Cells to the Dual Erbb Receptor Tyrosine Kinase Inhibitor Lapatinib (GW572016)
- TYKERB (Lapatinib) Tablets ------WARNINGS and PRECAUTIONS ------Initial U.S
- Antimalarial Activity of Kinase Inhibitor, Nilotinib, in Vitro and in Vivo
- Active Kinase Profiling, Genetic and Pharmacological Data Define Mtor
- Primary Breast Cancer Cell Culture Yields Intra-Tumor Heterogeneous
- Breast02 Randomize
- The Efficacy of Lapatinib and Nilotinib in Combination with Radiation Therapy in a Model of NF2 Associated Peripheral Schwannoma
- Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2
- Risk Assessment and Risk Mitigation Review(S)